LFA
CSCI

Legacy Financial Advisors’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Legacy Financial Advisors’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-180
Closed -$14K – 209
2021
Q3 		$14K Hold
180
– – ﹤0.01% 183
2021
Q2 		$16K Hold
180
– – ﹤0.01% 173
2021
Q1 		$21K Buy
+180
New +$20K 0.01% 158

Other funds holding CSCI

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legacy Financial Advisors's CSCI Position: Q4 2021 in Review

Legacy Financial Advisors sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q4 2021, closing a stake of 180 shares — an estimated $14K sold.

Legacy Financial Advisors first reported a position in CSCI in Q1 2021 and held it in 3 quarters. The position peaked at $21K in Q1 2021. 29 funds tracked by Wall St. Rank hold CSCI as of Q4 2021.

  • Legacy Financial Advisors reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Legacy Financial Advisors sold 180 COSCIENS Biopharma Inc. Common Stock shares in Q4 2021, an estimated $14K.
  • Legacy Financial Advisors first reported a position in COSCIENS Biopharma Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Legacy Financial Advisors's COSCIENS Biopharma Inc. Common Stock position peaked at $21K in Q1 2021.
  • 29 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q4 2021.

Based on Legacy Financial Advisors's 13F filing for Q4 2021, filed 4 Feb 2022.